Mosley Wealth Management Sells 106 Shares of Eli Lilly and Company (NYSE:LLY)

Mosley Wealth Management reduced its position in Eli Lilly and Company (NYSE:LLY) by 10.5% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 908 shares of the company’s stock after selling 106 shares during the period. Eli Lilly and Company makes up 0.7% of Mosley Wealth Management’s investment portfolio, making the stock its 27th largest holding. Mosley Wealth Management’s holdings in Eli Lilly and Company were worth $822,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of the business. Tidemark LLC bought a new position in shares of Eli Lilly and Company in the fourth quarter valued at approximately $29,000. Core Wealth Advisors Inc. lifted its stake in Eli Lilly and Company by 188.2% during the 4th quarter. Core Wealth Advisors Inc. now owns 49 shares of the company’s stock valued at $29,000 after acquiring an additional 32 shares in the last quarter. Lynx Investment Advisory purchased a new position in Eli Lilly and Company during the 2nd quarter worth $32,000. LGT Financial Advisors LLC bought a new stake in shares of Eli Lilly and Company in the 2nd quarter worth $36,000. Finally, Frank Rimerman Advisors LLC purchased a new stake in shares of Eli Lilly and Company in the fourth quarter valued at about $37,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Stock Performance

Shares of Eli Lilly and Company stock traded down $10.04 during trading hours on Friday, reaching $902.71. The company had a trading volume of 3,439,999 shares, compared to its average volume of 3,063,074. The firm has a market cap of $857.94 billion, a PE ratio of 132.95, a price-to-earnings-growth ratio of 2.91 and a beta of 0.41. Eli Lilly and Company has a one year low of $516.57 and a one year high of $972.53. The company has a debt-to-equity ratio of 1.74, a current ratio of 1.11 and a quick ratio of 0.87. The business has a fifty day simple moving average of $895.97 and a 200 day simple moving average of $827.49.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, August 8th. The company reported $3.92 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.64 by $1.28. The business had revenue of $11.30 billion for the quarter, compared to analysts’ expectations of $9.83 billion. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. On average, analysts anticipate that Eli Lilly and Company will post 16.51 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Thursday, August 15th will be given a $1.30 dividend. The ex-dividend date is Thursday, August 15th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.58%. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 76.58%.

Analysts Set New Price Targets

A number of brokerages have issued reports on LLY. Berenberg Bank upped their price objective on shares of Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the stock a “buy” rating in a research report on Wednesday, August 14th. Bank of America upped their target price on Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the company a “buy” rating in a report on Friday, August 9th. Evercore ISI upgraded Eli Lilly and Company to a “hold” rating in a report on Thursday. Wells Fargo & Company lifted their target price on Eli Lilly and Company from $875.00 to $1,000.00 and gave the stock an “overweight” rating in a research note on Friday, August 9th. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating and increased their price target for the company from $725.00 to $1,025.00 in a research report on Monday, August 12th. Three equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $961.76.

Insider Activity at Eli Lilly and Company

In other news, major shareholder Lilly Endowment Inc sold 15,022 shares of the company’s stock in a transaction on Friday, June 14th. The shares were sold at an average price of $882.47, for a total value of $13,256,464.34. Following the transaction, the insider now owns 97,778,788 shares of the company’s stock, valued at $86,286,847,046.36. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Over the last 90 days, insiders sold 737,410 shares of company stock valued at $669,719,100. Corporate insiders own 0.13% of the company’s stock.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.